自身免疫性肝炎相关肝细胞癌的研究进展

郭文沛; 张海燕; 刘立新

doi:10.3969/j.issn.1001-5256.2022.06.044

自身免疫性肝炎相关肝细胞癌的研究进展

DOI: 10.3969/j.issn.1001-5256.2022.06.044

郭文沛^{1, 2a},
张海燕^{2a, 2b, 2c, 2d},
刘立新^{1, 2a, 2b, 2c, 2d, , ,}

1.
山西医科大学第一临床医学院，太原 030001
2a.
山西医科大学第一医院消化内科，太原 030001
2b.
山西医科大学第一医院科研实验中心，太原 030001
2c.
山西医科大学第一医院肝损伤与消化道肿瘤防治委级重点实验室，太原 030001
2d.
山西医科大学第一医院肝病与器官移植研究所，太原 030001

基金项目:

中央引导地方科技发展资金(山西省科技厅) (YDZX20201400001965)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：郭文沛负责课题设计，查阅文献，撰写论文；张海燕负责文章修改；刘立新参与文献审核、指导撰写文章并最后定稿。

详细信息

通信作者:
刘立新，lixinliu6@hotmail.com

计量
- 文章访问数: 682
- HTML全文浏览量: 203
- PDF下载量: 80
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-31
- 录用日期: 2021-12-15
- 出版日期: 2022-06-20

Research advances in autoimmune hepatitis-related hepatocellular carcinoma

Wenpei GUO^{1, 2a},
Haiyan ZHANG^{2a, 2b, 2c, 2d},
Lixin LIU^{1, 2a, 2b, 2c, 2d
, ,
,}

1.
The First Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China
2a.
Department of Gastroenterology, First Hospital of Shanxi Medical University, Taiyuan 030001, China
2b.
Experimental Center of Science and Research, First Hospital of Shanxi Medical University, Taiyuan 030001, China
2c.
Committee-level Key Laboratory of Liver Injury and Gastrointestinal Tumor Prevention and Treatment, First Hospital of Shanxi Medical University, Taiyuan 030001, China
2d.
Institute of Liver Disease and Organ Transplantation, First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

The Funding of Scientific and Technological Development with Central Government Guiding Local (Department of Science and Technology of Shanxi Province) (YDZX20201400001965)

More Information

Corresponding author: LIU Lixin, lixinliu6@hotmail.com (ORCID: 0000-0001-7585-9432)

摘要

摘要: 自身免疫性肝炎(AIH)相关肝细胞癌(HCC)是指在长期AIH的基础上发生的HCC，其发病率较低(0~6%)。高龄、男性、糖尿病、酒精使用、AIH反复复发与持续ALT异常、免疫抑制治疗和治疗失败及长期肝硬化状态等可能是AIH患者发生HCC的危险因素。肝硬化是AIH发生HCC的重要阶段。AIH进展到肝硬化后，HCC发病率显著升高。目前国内外关于AIH发生HCC的机制鲜有报道，可能与肝硬化诱导下特异性分子生物学特征(染色体、端粒、基因等)的改变、细胞死亡-炎症-癌症途径及肠道微生态紊乱等有关。及时识别AIH可能发展为HCC的高危人群并加强干预、随访和监测非常重要。
- 肝炎, 自身免疫性 /
- 癌, 肝细胞 /
- 肝硬化 /
- 危险因素
Abstract: Autoimmune hepatitis (AIH)-related hepatocellular carcinoma (HCC) is defined as HCC that develops on the basis of long-term AIH and has a relatively low incidence rate of 0-6%. The risk factors for HCC in AIH patients include old age, male sex, diabetes, alcohol use, AIH recurrence and persistent alanine aminotransferase abnormalities, failure in immunosuppressive therapy and related treatments, and long-term liver cirrhosis. Liver cirrhosis is an important stage for the development of HCC in AIH, and the incidence rate of HCC increases significantly after AIH progresses to liver cirrhosis. At present, there are few reports on the mechanism of HCC in AIH, which may be associated with the changes in specific molecular biological characteristics (including chromosomes, telomeres, and genes) induced by liver cirrhosis, the cell death-inflammation-cancer pathway, and intestinal microecological disorders. It is of great importance to identify the AIH population at a high risk of HCC in a timely manner and enhance intervention, follow-up, and monitoring.
- Hepatitis, Autoimmune /
- Carcinoma, Hepatocellular /
- Liver Cirrhosis /
- Risk Factors

HTML全文

参考文献(45)

[1]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis[J]. J Hepatol, 2015, 63(4): 971-1004. DOI: 10.1016/j.jhep.2015.06.030.
[2]	Bureau of Medical Administration National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36 (2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[3]	WANG G, TANAKA A, ZHAO H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis[J]. Hepatol Int, 2021, 15(2): 223-257. DOI: 10.1007/s12072-021-10170-1.
[4]	SATAKE Y, TAKADA K, IKEDA K, et al. A case of primary liver cell cancer complicating lupoid hepatitis[J]. Jpn J Med, 1988, 27(1): 83-86. DOI: 10.2169/internalmedicine1962.27.83.
[5]	JOHNSON PJ, MCFARLANE IG. Meeting report: International Autoimmune Hepatitis Group[J]. Hepatology, 1993, 18(4): 998-1005. DOI: 10.1002/hep.1840180435.
[6]	PARK SZ, NAGORNEY DM, CZAJA AJ. Hepatocellular carcinoma in autoimmune hepatitis[J]. Dig Dis Sci, 2000, 45(10): 1944-1948. DOI: 10.1023/a:1005638500236.
[7]	ALVAREZ F, BERG PA, BIANCHI FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
[8]	HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
[9]	de LUCA-JOHNSON J, WANGENSTEEN KJ, HANSON J, et al. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease[J]. Dig Dis Sci, 2016, 61(9): 2710-2720. DOI: 10.1007/s10620-016-4213-3.
[10]	HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. DOI: 10.1038/s41575-020-00381-6.
[11]	TAKAHASHI A, ARINAGA-HINO T, OHIRA H, et al. Non-alcoholic fatty liver disease in patients with autoimmune hepatitis[J]. JGH Open, 2018, 2(2): 54-58. DOI: 10.1002/jgh3.12046.
[12]	TANSEL A, KATZ LH, EL-SERAG HB, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: A systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217. e4. DOI: 10.1016/j.cgh.2017.02.006.
[13]	VALEAN S, ACALOVSCHI M, DUMITRASCU DL, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis-a systematic review of the literature published between 1989-2016[J]. Med Pharm Rep, 2019, 92(2): 99-105. DOI: 10.15386/mpr-1228.
[14]	YAN LJ, YAO SY, MENG GX, et al. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis[J]. Hepatol Int, 2021, 15(6): 1413-1420. DOI: 10.1007/s12072-021-10249-9.
[15]	CZAJA AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis[J]. Dig Dis Sci, 2013, 58(6): 1459-1476. DOI: 10.1007/s10620-012-2525-5.
[16]	SINGAL AG, LAMPERTICO P, NAHON P. Epidemiology and surveillance for hepatocellular carcinoma: New trends[J]. J Hepatol, 2020, 72(2): 250-261. DOI: 10.1016/j.jhep.2019.08.025.
[17]	XING GQ, JIA ZS. Analysis of clinical characteristics and prognostic risk factors of autoimmune hepatitis (AIH) -associated hepatocellular carcinoma (HCC)[J]. China Health Care Nutrition, 2015, 25(8): 218. 邢国权, 贾智硕. 自身免疫性肝炎(AIH)相关肝癌(HCC)的临床特点和预后危险因素分析[J]. 中国保健营养, 2015, 25(8): 218.
[18]	MACARON C, HANOUNEH I, LOPEZ R. Incidence and risk factors of hepatocellular carcinoma in patients with primary biliary cirrhosis and autoimmune hepatitis[J]. Gastroenterology, 2010, 138: S809.
[19]	WATANABE T, SOGA K, HIRONO H, et al. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis[J]. World J Gastroenterol, 2009, 15(2): 231-239. DOI: 10.3748/wjg.15.231.
[20]	KALRA M, MAYES J, ASSEFA S, et al. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma[J]. World J Gastroenterol, 2008, 14(39): 5945-5961. DOI: 10.3748/wjg.14.5945.
[21]	HINO-ARINAGA T, IDE T, KUROMATSU R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1[J]. J Gastroenterol, 2012, 47(5): 569-576. DOI: 10.1007/s00535-011-0519-2.
[22]	VAZ NF, MARGON JF, MOUTINHO BD, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis: prevalence and risk factors[J]. J Hepatol, 2020, 73: S401-S652. DOI: 10.1016/S0168-8278(20)31412-4.
[23]	LUO X, ZHANG YM. The research progress of relation between diabetes and hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2020, 26(9): 717-720. DOI: 10.3760/cma.j.cn113884-20190917-00302. 罗希, 张雅敏. 糖尿病与肝细胞癌的相关研究进展[J]. 中华肝胆外科杂志, 2020, 26 (9): 717-720. DOI: 10.3760/cma.j.cn113884-20190917-00302.
[24]	RAMADORI P, CUBERO FJ, LIEDTKE C, et al. Alcohol and hepatocellular carcinoma: Adding fuel to the flame[J]. Cancers (Basel), 2017, 9(10): 130. DOI: 10.3390/cancers9100130.
[25]	ZHANG MY, HAN L, SUN Y, et al. Research advances in clinical treatment of adult autoimmune hepatitis[J]. J Clin Hepatol, 2021, 37(6): 1459-1465. DOI: 10.3969/j.issn.1001-5256.2021.06.050. 张明月, 韩琳, 孙颖, 等. 成人自身免疫性肝炎临床治疗进展[J]. 临床肝胆病杂志, 2021, 37(6): 1459-1465. DOI: 10.3969/j.issn.1001-5256.2021.06.050.
[26]	YOSHIZAWA K, MATSUMOTO A, ICHIJO T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis[J]. Hepatology, 2012, 56(2): 668-676. DOI: 10.1002/hep.25658.
[27]	MONTANO-LOZA AJ, CARPENTER HA, CZAJA AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis[J]. Am J Gastroenterol, 2008, 103(8): 1944-1951. DOI: 10.1111/j.1572-0241.2008.01922.x.
[28]	MIYAKE Y, IWASAKI Y, TERADA R, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis[J]. Aliment Pharmacol Ther, 2006, 24(8): 1197-1205. DOI: 10.1111/j.1365-2036.2006.03113.x.
[29]	FARRAYE FA, MELMED GY, LICHTENSTEIN GR, et al. ACG Clinical Guideline: Preventive care in inflammatory bowel disease[J]. Am J Gastroenterol, 2017, 112(2): 241-258. DOI: 10.1038/ajg.2016.537.
[30]	JENSEN MD, JEPSEN P, VILSTRUP H, et al. Increased cancer risk in autoimmune hepatitis: A danish nationwide cohort study[J]. Am J Gastroenterol, 2022, 117(1): 129-137. DOI: 10.14309/ajg.0000000000001525.
[31]	SHARMA R, VERNA EC, SIMON TG, et al. Cancer risk in patients with autoimmune hepatitis: A nationwide population-based cohort study with histopathology[J]. Am J Epidemiol, 2022, 191(2): 298-319. DOI: 10.1093/aje/kwab119.
[32]	TARAO K, NOZAKI A, IKEDA T, et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment[J]. Cancer Med, 2019, 8(3): 1054-1065. DOI: 10.1002/cam4.1998.
[33]	WANG LP, WU LZ. Diagnosis and differential diagnosis of well differentiated hepatocellular carcinoma and precancerous lesions—update and progress of WHO digestive system tumor hepatocellular carcinoma, Fifth Edition, 2019[J]. Chin J Diagn Pathol, 2020, 27(7): 495-498. DOI: 10.3969/j.issn.1007-8096.2020.07.012. 王鲁平, 武丽真. 分化好的肝细胞癌及癌前病变的诊断及鉴别诊断——2019年第五版WHO消化系统肿瘤肝细胞癌的更新及进展[J]. 诊断病理学杂志, 2020, 27(7): 495-498. DOI: 10.3969/j.issn.1007-8096.2020.07.012.
[34]	Chinese Journal of Hepatology; Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)[J]. J Clin Hepatol, 2020, 36(3): 514-518. DOI: 10.3969/j.issn.1001-5256.2020.03.007. 《中华肝脏病杂志》编辑委员会, 中华医学会肝病学分会肝癌学组. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(3): 514-518. DOI: 10.3969/j.issn.1001-5256.2020.03.007
[35]	LUEDDE T, KAPLOWITZ N, SCHWABE RF. Cell death and cell death responses in liver disease: Mechanisms and clinical relevance[J]. Gastroenterology, 2014, 147(4): 765-783. e4. DOI: 10.1053/j.gastro.2014.07.018.
[36]	LIU Q, DING GR, HUI YF, et al. Study on HMGB1 and its receptors RAGE molecular signaling pathway involved in regulating the mechanism of proliferation and infiltrative migration of HCC[J]. J Clin Exp Med, 2017, 16(3): 213-217. DOI: 10.3969/j.issn.1671-4695.2017.03.002. 刘清, 丁光仁, 惠永峰, 等. HMGB1及其受体RAGE分子信号通路参与调节肝细胞肝癌增殖和侵袭迁移机制的研究[J]. 临床和实验医学杂志, 2017, 16(3): 213-217. DOI: 10.3969/j.issn.1671-4695.2017.03.002.
[37]	WANG K, LI JT, YAN SG, et al. Effects of intestinal microecology on malignant transformation of liver cirrhosis liver precancerous lesion[J]. Chin J Gastroenterol Hepatol, 2018, 27(1): 111-114. DOI: 10.3969/j.issn.1006-5709.2018.01.025. 王轲, 李京涛, 闫曙光, 等. 肠道微生态对肝硬化-肝癌癌前病变恶性转变的影响[J]. 胃肠病学和肝病学杂志, 2018, 27(1): 111-114. DOI: 10.3969/j.issn.1006-5709.2018.01.025.
[38]	LU YX, YANG CQ. Advances in intestinal microecology and chronic liver disease[J]. Chin Hepatol, 2019, 24(1): 92-95. DOI: 10.3969/j.issn.1008-1704.2019.01.031. 卢峪霞, 杨长青. 肠道微生态与慢性肝病研究进展[J]. 肝脏, 2019, 24(1): 92-95. DOI: 10.3969/j.issn.1008-1704.2019.01.031.
[39]	SAHEBJAM F, VIERLING JM. Autoimmune hepatitis[J]. Front Med, 2015, 9(2): 187-219. DOI: 10.1007/s11684-015-0386-y.
[40]	SHENG SP, WANG HY, LI JJ, et al. Clinical features, treatment and prognosis of primary liver cancer associated with autoimmune hepatitis[J]. Chin J Gastroenterol Hepatol, 2020, 29(1): 15-17. DOI: 10.3969/j.issn.1006-5709.2020.01.003. 生守鹏, 王海燕, 李建军, 等. 自身免疫性肝炎相关原发性肝癌的临床特征、治疗及预后[J]. 胃肠病学和肝病学杂志, 2020, 29(1): 15-17. DOI: 10.3969/j.issn.1006-5709.2020.01.003.
[41]	SONG ZY, PAN Q, YU Y, et al. Pairing analysis of clinical prognosis between liver transplantation with autoimmune liver disease and viral hepatitis cirrhosis[J]. Ogran Transplant, 2020, 11(1): 82-86. DOI: 10.3969/j.issn.1674-7445.2020.01.013. 宋占宇, 潘崎, 于杨, 等. 自身免疫性肝病与病毒性肝炎肝硬化肝移植预后差异配对分析[J]. 器官移植, 2020, 11(1): 82-86. DOI: 10.3969/j.issn.1674-7445.2020.01.013.
[42]	WATANABE T, SOGA K, HIRONO H, et al. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis[J]. World J Gastroenterol, 2009, 15(2): 231-239. DOI: 10.3748/wjg.15.231.
[43]	MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913.
[44]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[45]	TANAKA A. Autoimmune hepatitis: 2019 update[J]. Gut Liver, 2020, 14(4): 430-438. DOI: 10.5009/gnl19261.